small molecule

EKTERLY

SEBETRALSTAT

Loss of exclusivityJanuary 2039latest FDA-listed patent expiry

CompanyKalVista Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	EKTERLY
Active ingredient	SEBETRALSTAT
Strength	300MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	July 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
11234939	January 2039	product
11230537	December 2037	substance, product
11739068	June 2037	use U-4223
11084809	November 2035	substance, product
10611758	November 2035	use U-4223
10364238	November 2035	substance, product
11001578	November 2035	substance, product
11198691	November 2035	use U-4223

Regulatory exclusivity

Code	Expires
ODE-534	July 2032
NCE	July 2030

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.